PREMIR

PREMIR is a blood test that screens for breast cancer in high risk women

  • Quick and simple:
    A minimally-invasive one-time blood draw
  • Reduced emotional stress: 
    Reduce unnecessary biopsies
  • Highly accurate: 
    miRNA specific biomarkers with AI
PREMIR test box sample

Why Should We Care?

1 out of 8 women are diagnosed with breast cancer at some point in their lifetime1

PREMIR can be used to accurately detect Breast Cancer at a very early stage. PREMIR can facilitate screening for high risk women, who are not served by the current screening modality; mammography.

Candidates for PREMIR2,3,4:

- Women with dense breasts about 30M

- Women with BRCA1/BRCA2 mutation about 400,000

- Women with family history of breast cancer about 800,000

High false positive rate:

- 38.6M mammograms are done annually, of which 50% will have a false positive result over a ten year period1

- 6.5M women with dense breasts may have a false positive result with mammograms2

Excessive follow-ups4:

About 4.4M (12%) of women require follow-up imaging or biopsy after mammogram screening, but 95% of these women do not have cancer

How Can PREMIR Help Your Patients?

simple blood test icon

Simple blood test

One 10ml tube of blood

improved patient care icon

Improved patient care

Detection of breast cancer with high accuracy, earlier, and reducing unnecessary invasive testing and anxiety for the patient

Benefits For High-Risk Patients

Family History

  • Up to 30% of those diagnosed with breast cancer have a positive family history5
  • The risk of breast cancer is about two times higher for women with one first-degree relative with breast cancer, compared to women without a family history6

Age

  • The incidence of breast cancer increases with age
  • 82% of invasive breast cancer is diagnosed in women age 50 and older7
  • The risk of breast cancer is highest for women in their 60s with 28% of invasive breast cancers diagnosed in women in their 60s8

Dense Breasts

A dense breast is when the breasts are composed of dense tissue for more than 50% of the breast area compared with the non-dense tissue (Fig. A).

50% of women have dense breast (~30m or more women in the United States) dense breasts are particularly common in younger women under the 60s.9

Challenges

Women with dense breasts are more prone to getting false-positive results because the dense tissues block X-ray. Hence more likely to appear white which makes it difficult to distinguish from the tumor.

Also, dense breasts is an independent risk factor for having an increased rate of developing breast cancer.10

dense breast infographic

(Fig. A) https://www.acr.org/-/media/ACR/Files/Breast-Imaging-Resources/Breast-Density-bro_ACR_SBI.pdf

BRCA

  • BRCA mutation is a mutation in either BRCA1 or BRCA2 genes which are tumor suppressor genes (Fig. B)11
  • The prevalence of BRCA mutation is about 1 in 400
  • BRCA mutations are responsible for only about 5-10% of all breast cancers12,13
  • Annual breast MRI beginning at age 25 and addition of annual mammography at age 30 is recommended for women who carry a BRCA mutation14
genetic mutations brca infographic

(Fig. B) MyHealth.Alberta.ca Non-BRCA Gene Mutations That Raise Breast Cancer Risk (verywellhealth.com)

Atypical Hyperplasia

Cell growth in the normally hollow glandular structures is called hyperplasia (Fig.C).

Although atypical cells are abnormal, they are benign and not cancerous. The conditions are usually diagnosed after a needle biopsy of the breast.

Atypical hyperplasia is associated with an increased risk of breast cancer in the future, even if the atypia is surgically removed. The risk for breast cancer is 3 or 4 times the risk of the average woman.15

atypical hyperplasia infographic

(Fig. C) https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-types-grades/types/ductal-carcinoma-in-situ-dcis

DCIS

Ductal carcinoma in situ (DCIS) is the presence of abnormal cells in the lining of the milk duct in the breast. (Fig. D) DCIS is the earliest form of breast cancer (stage 0) and is non-invasive cancer. If DCIS is left untreated, it has the potential to progress to an invasive cancer.16

Overall, DCIS accounts for 20% of all newly diagnosed breast cancers each year.17

DCIS is usually detected on a mammogram. When suspicious findings are seen, a breast biopsy is recommended.18

dcis infographic

(Fig. D) https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-types-grades/types/ductal-carcinoma-in-situ-dcis

LCIS

Lobular carcinoma in situ (LCIS) is the presence of atypical cells in the lobules of the breast which are the milk-producing glands at the end of breast ducts (Fig. E).

LCIS is not true cancer and is considered a high-risk lesion that increases the risk of developing invasive breast cancer.19

One estimate is that the lifetime risk of developing invasive breast cancer is 30-40% for women with LCIS, versus a lifetime risk of 12.5% for the average woman.20

LCIS is most often discovered as a result of a breast biopsy done for another reason, and usually does not cause symptoms or show up on a mammogram.21

Although LCIS is a relatively rare finding, it is seen in approximately 0.5% to 4% of benign breast biopsies.22

lcis infographic

(Fig. E) https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-types-grades/types/lobular-carcinoma-in-situ-lcis

DROPLET-BC Study

Detection by circulating RNA with OPtimized  machine LEarning Technology for Breast Cancer: a prospective clinical trial based in the U.S. in progress

Learn More

Our Technology

Learn how we detect cancer early from a single blood test

Learn More
preferred medicine technology graphic

Stay Informed

Sign up to be the first to hear any updates

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Please try again.
We use cookies to provide you with a greater online experience. By using our sites, you agree to our use of cookies. See our cookie policy.